CIENCIASMEDICASNEWS: Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial - The Lancet Respiratory Medicine

domingo, 18 de julio de 2021

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial - The Lancet Respiratory Medicine

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial - The Lancet Respiratory Medicine

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)